Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Theravance Biopharma benefits from record sales growth, upcoming Phase 3 CYPRESS data expected Q1 2026 as a key catalyst, positive technical momentum (+27% last month), and strong sector tailwinds, supporting near-term upside despite ongoing losses and high valuation.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Revenue Decline ⢠Negative Cash Flow TBPH has strong liquidity and low leverage, but sharp revenue contraction, renewed losses, and negative cash flow make the current valuation difficult to justify on operating fundamentals.
Price Behavior
Key Price Behavior Insights: ⢠Mild upward drift ⢠Tight consolidation ⢠Resistance capped Support Level: $16.95â$17.01 Resistance Level: $17.06â$17.08 TBPH consolidated with mild upward drift over the last month, holding $16.95â$17.01 support but needing a sustained break above $17.08 to turn constructive.
Sentiment & News
Key News Insights: ⢠Above 50-day ⢠Post-earnings gain ⢠Analyst uncertainty TBPH's move above its 50-day average and modest post-earnings gain signal improving technical momentum, though analyst sentiment remains unclear.
AI Summary
TBPH is now primarily a merger-arbitrage trade: buying near $17 offers minimal closing-related upside, while the only meaningful incremental return is the highly uncertain, long-dated ampreloxetine CVR; investors should focus on closing conditions and treat the CVR as speculative optionality rather than core value.
Description
Theravance Biopharma is a biopharmaceutical company that researches, develops and commercializes respiratory medicines across the United States, Europe and Asia, with YUPELRI sold as a nebulized, once-daily therapy for COPD. Its clinical pipeline includes inhaled and gut-targeted small moleculesânotably several JAK inhibitors and other candidates addressing pulmonary and gastrointestinal disordersâalongside later-stage programs for autonomic and motility conditions. The company maintains licensing and collaboration agreements with major pharmaceutical partners and is incorporated in 2013 with headquarters in George Town, Cayman Islands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 5 | Dec 12 | TBPH | Theravance Biopharma, Inc. | Theravance Biopharma benefits from record sales growth, upcoming Phase 3 CYPRESS data expected Q1 2026 as a key catalyst, positive technical momentum (+27% last month), and strong sector tailwinds, supporting near-term upside despite ongoing losses and high valuation. | Closed | -2.1% |